Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Half-Dose of Novartis Flu Vaccine Gives Immunity

By Drug Discovery Trends Editor | November 18, 2009

BASEL, Switzerland (AP) – Pharmaceutical maker Novartis AG said a U.S. clinical study suggests that half a dose of its swine flu vaccine may be sufficient to protect people from the virus and could allow many more to be immunized with current supplies.

Clinical trials of around 4,000 individuals have shown that half the current dose of its U.S.-approved vaccine Fluvirin gives immunity to adults, the Swiss drug maker said in a statement.

The company’s swine flu vaccine for the U.S. contains no adjuvant, a chemical compound that hasn’t been approved by the U.S. Food and Drug Administration but which often is used in vaccines sold in other countries to boost the immune system and stretch the vaccine’s active ingredient.

Novartis is discussing the findings with the Food and Drug Administration, which is assessing whether the amount of vaccine per dose can be reduced in the United States.

In Europe, Novartis has been using an adjuvant for flu vaccines since 1997. A separate study of more than 33,000 participants showed that the adjuvant is well tolerated, the company said. A single shot containing the adjuvant and half the amount of vaccine used in Fluvirin is enough to protect children between 3 and 8 and adults, according to the study.

Novartis said using the adjuvant in the U.S. could allow the immunization of four times more people with current vaccine supplies.

Date: November 17, 2009
Source: Associated Press


Filed Under: Drug Discovery

 

Related Articles Read More >

Lokavant’s Spectrum v15 uses AI to cut trial-feasibility modeling from weeks to minutes
Prime time for peptide-based drug discovery 
Why smaller, simpler molecular glues are gaining attention in drug discovery
Glass vial, pipette and woman scientist in laboratory for medical study, research or experiment. Test tube, dropper and professional female person with chemical liquid for pharmaceutical innovation
Unlocking ‘bench-to-bedside’ discoveries requires better data sharing and collaboration
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE